@article {8031,
	title = {Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: A phase III study conducted by the Hellenic Cooperative Oncology Group},
	journal = {Annals of Oncology},
	volume = {15},
	year = {2004},
	note = {Cited By :53Export Date: 21 February 2017},
	month = {2004},
	pages = {1517 - 1526},
	abstract = {Background: To compare survival between patients with advanced breast cancer (ABC) treated with epirubicin/paclitaxel (Taxol) or paclitaxel/carboplatin (Cp) chemotherapy. Patients and methods: From January 1999 to April 2002, 327 eligible patients with ABC were randomized to receive either paclitaxel 175 mg/m2 in a 3-h infusion followed by epirubicin (EPI) 80 mg/m2 (group A) or paclitaxel, as in group A, followed by Cp at an AUC of 6 mg {\texttimes} min/ml (group, B) every 3 weeks for six cycles. Results: After a median follow-up of 23.5 months, median survival was not significantly different between the two groups (22.4 months versus 27.8 months, P = 0.25), whereas median time to treatment failure was significantly longer in patients treated with paclitaxel/Cp (8.1 months in group A versus 10.8 months in group B, P=0.04). Both regimens were well tolerated. In total, 39 patients (24\%) in group A and 46 (29\%) in group B suffered at least one severe side-effect. Quality-of-life assessment and cost analysis did not reveal any significant differences between the two groups. Conclusion: Our study suggests that the paclitaxel/Cp combination is an effective therapeutic alternative for patients with ABC in which anthracycline administration has the potential of being harmful. {\textcopyright} 2004 European Society for Medical Oncology.},
	keywords = {Antracyclines, breast cancer, Carboplatin, Chemotherapy, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-4944267230\&doi=10.1093\%2fannonc\%2fmdh395\&partnerID=40\&md5=dc566ab905b3694f6d87813a6770d6c7},
	author = {Fountzilas, G. and Kalofonos, H.P. and Dafni, U. and Papadimitriou, C. and Bafaloukos, D. and Papakostas, P. and Kalogera-Fountzila, A. and Gogas, H. and Aravantinos, G. and Moulopoulos, L.A. and Economopoulos, T. and Pectasides, D. and Maniadakis, N. and Siafaka, V. and Briasoulis, E. and Christodoulou, C. and Tsavdaridis, D. and Makrantonakis, P. and Razis, E. and Kosmidis, P. and Skarlos, D. and Dimopoulos, M.A.}
}
